NCT00320619

Brief Summary

Individuals who undergo spine surgery often have a significant loss of blood and may require multiple blood transfusions. Research has shown that epsilon-aminocaproic acid (EACA) may reduce the amount of blood lost during surgery, which would decrease the number of blood transfusions required. This study will evaluate the safety and effectiveness of EACA at reducing blood loss and the need for blood transfusions in individuals undergoing spine surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
182

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2000

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2000

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2006

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 3, 2006

Completed
Last Updated

July 29, 2016

Status Verified

March 1, 2009

Enrollment Period

5.4 years

First QC Date

April 28, 2006

Last Update Submit

July 28, 2016

Conditions

Keywords

Aminocaproic AcidsBlood Transfusion

Outcome Measures

Primary Outcomes (1)

  • Number of allogenic blood units transfused

    Measured through the 8th postoperative day

Secondary Outcomes (10)

  • Intraoperative and postoperative blood loss

    Measured through the 8th postoperative day

  • Intraoperative and postoperative blood products received, including autologous blood, allogenic blood, fresh frozen plasma, platelets, or cryo

    Measured through the 8th postoperative day

  • Potential complications of transfusion

    Measured through the 8th postoperative day

  • Potential complications of EACA

    Measured through the 8th postoperative day

  • Potential surgical complications

    Measured through the 8th postoperative day

  • +5 more secondary outcomes

Study Arms (2)

1

EXPERIMENTAL

Participants will receive either EACA.

Drug: Epsilon-Aminocaproic Acid (EACA)

2

PLACEBO COMPARATOR

Participants will receive placebo.

Drug: Placebo

Interventions

Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).

1

Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of spondylosis, pseudoarthrosis, kyphoscoliosis, or acquired or congenital spine deformity
  • Willing to undergo elective spinal surgery by a participating surgeon; eligible procedures include the following: spine osteotomy, arthrodesis, instrumentation and/or corpectomy, surgery for lumbar spinal stenosis, or surgery for degenerative disc disease

You may not qualify if:

  • Requires urgent or emergent surgery
  • Has kidney failure that requires dialysis
  • Has a known bleeding diathesis, defined as a documented history of an inherited bleeding disorder (e.g., hemophilia or von Willebrand's disease) OR prothrombin time ratio greater than 1.5 seconds OR a documented previous arterial or venous thrombosis within 1 year of study entry
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

Location

Related Publications (5)

  • Goodnough LT, Bach RG. Anemia, transfusion, and mortality. N Engl J Med. 2001 Oct 25;345(17):1272-4. doi: 10.1056/NEJM200110253451711. No abstract available.

    PMID: 11680450BACKGROUND
  • Troianos CA, Sypula RW, Lucas DM, D'Amico F, Mathie TB, Desai M, Pasqual RT, Pellegrini RV, Newfeld ML. The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology. 1999 Aug;91(2):430-5. doi: 10.1097/00000542-199908000-00017.

    PMID: 10443606BACKGROUND
  • Slaughter TF, Faghih F, Greenberg CS, Leslie JB, Sladen RN. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg. 1997 Dec;85(6):1221-6. doi: 10.1097/00000539-199712000-00008.

    PMID: 9390584BACKGROUND
  • Florentino-Pineda I, Thompson GH, Poe-Kochert C, Huang RP, Haber LL, Blakemore LC. The effect of amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study. Spine (Phila Pa 1976). 2004 Feb 1;29(3):233-8. doi: 10.1097/01.brs.0000109883.18015.b9.

    PMID: 14752343BACKGROUND
  • Berenholtz SM, Pham JC, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB, Nundy S, Dorman T, Ness PM, Klag MJ, Pronovost PJ, Kebaish KM. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096-103. doi: 10.1097/BRS.0b013e3181b1fab2.

MeSH Terms

Conditions

ScoliosisKyphosisLordosisSpondylitisSpinal Stenosis

Interventions

Aminocaproic Acid

Condition Hierarchy (Ancestors)

Spinal CurvaturesSpinal DiseasesBone DiseasesMusculoskeletal DiseasesBone Diseases, InfectiousInfections

Intervention Hierarchy (Ancestors)

AminocaproatesCaproatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Sean Berenholtz, MD, MHS

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

April 28, 2006

First Posted

May 3, 2006

Study Start

September 1, 2000

Primary Completion

February 1, 2006

Study Completion

February 1, 2006

Last Updated

July 29, 2016

Record last verified: 2009-03

Locations